DE60336576D1 - Hemmer der akt aktivität - Google Patents

Hemmer der akt aktivität

Info

Publication number
DE60336576D1
DE60336576D1 DE60336576T DE60336576T DE60336576D1 DE 60336576 D1 DE60336576 D1 DE 60336576D1 DE 60336576 T DE60336576 T DE 60336576T DE 60336576 T DE60336576 T DE 60336576T DE 60336576 D1 DE60336576 D1 DE 60336576D1
Authority
DE
Germany
Prior art keywords
compounds
hemmer
activity
act activity
directed
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60336576T
Other languages
English (en)
Inventor
Mark E Duggan
Craig W Lindsley
Zhijian Zhao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Merck Sharp and Dohme LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp and Dohme LLC filed Critical Merck Sharp and Dohme LLC
Application granted granted Critical
Publication of DE60336576D1 publication Critical patent/DE60336576D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE60336576T 2002-10-30 2003-10-24 Hemmer der akt aktivität Expired - Lifetime DE60336576D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42230702P 2002-10-30 2002-10-30
PCT/US2003/034007 WO2004041162A2 (en) 2002-10-30 2003-10-24 Inhibitors of akt activity

Publications (1)

Publication Number Publication Date
DE60336576D1 true DE60336576D1 (de) 2011-05-12

Family

ID=32312489

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60336576T Expired - Lifetime DE60336576D1 (de) 2002-10-30 2003-10-24 Hemmer der akt aktivität

Country Status (8)

Country Link
US (1) US7399764B2 (de)
EP (1) EP1558586B1 (de)
JP (1) JP2006507299A (de)
AT (1) ATE503483T1 (de)
AU (1) AU2003284981B2 (de)
CA (1) CA2501365C (de)
DE (1) DE60336576D1 (de)
WO (1) WO2004041162A2 (de)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004233826B2 (en) * 2003-04-24 2009-08-13 Merck Sharp & Dohme Corp. Inhibitors of Akt activity
CN1809351A (zh) * 2003-04-24 2006-07-26 麦克公司 Akt活性抑制剂
CA2522431A1 (en) 2003-04-24 2004-11-11 Merck & Co., Inc. Inhibitors of akt activity
US7414055B2 (en) * 2003-04-24 2008-08-19 Merck & Co., Inc. Inhibitors of Akt activity
CA2561311A1 (en) * 2004-04-09 2005-10-27 Merck & Co., Inc. Inhibitors of akt activity
JP2007532551A (ja) * 2004-04-09 2007-11-15 メルク　エンド　カムパニー　インコーポレーテッド Ａｋｔ活性の阻害剤
EP1784175A4 (de) * 2004-08-23 2009-07-22 Merck & Co Inc Inhibitoren von akt-aktivität
JP2008520745A (ja) 2004-11-22 2008-06-19 バーテックス ファーマシューティカルズ インコーポレイテッド Ｒｈｏキナーゼの二環式阻害剤
US8362075B2 (en) 2005-05-17 2013-01-29 Merck Sharp & Dohme Corp. Cyclohexyl sulphones for treatment of cancer
PT1898903E (pt) 2005-06-10 2013-06-28 Merck Sharp & Dohme Inibidores da atividade de akt
EP1978964A4 (de) 2006-01-24 2009-12-09 Merck & Co Inc Jak2-tyrosinkinase-hemmung
US8063050B2 (en) 2006-07-06 2011-11-22 Array Biopharma Inc. Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors
PL2049500T3 (pl) 2006-07-06 2012-02-29 Array Biopharma Inc Cyklopenta[d]pirymidyny jako inhibitory kinaz białkowych AKT
ATE532789T1 (de) 2006-07-06 2011-11-15 Array Biopharma Inc Dihydrothienopyrimidine als akt-proteinkinase- inhibitoren
DE602007011628D1 (de) 2006-07-06 2011-02-10 Array Biopharma Inc Dihydrofuropyrimidine als akt-proteinkinaseinhibitoren
US20100022573A1 (en) * 2006-12-06 2010-01-28 Layton Mark E Inhibitors of akt activity
AR064010A1 (es) * 2006-12-06 2009-03-04 Merck & Co Inc Inhibidores de la actividad de la akt
WO2008070823A2 (en) * 2006-12-07 2008-06-12 University Of South Florida Substrate-mimetic akt inhibitor
US9409886B2 (en) 2007-07-05 2016-08-09 Array Biopharma Inc. Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
US8377937B2 (en) 2007-07-05 2013-02-19 Array Biopharma Inc. Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
US8846683B2 (en) 2007-07-05 2014-09-30 Array Biopharma, Inc. Pyrimidyl cyclopentanes as Akt protein kinase inhibitors
CN103396409B (zh) 2007-07-05 2015-03-11 阵列生物制药公司 作为akt蛋白激酶抑制剂的嘧啶基环戊烷
US8835434B2 (en) 2008-01-09 2014-09-16 Array Biopharma, Inc. Hydroxylated pyrimidyl cyclopentanes as akt protein kinase inhibitors
US8853216B2 (en) 2008-01-09 2014-10-07 Array Biopharma, Inc. Hydroxylated pyrimidyl cyclopentane as AKT protein kinase inhibitor
US20100048913A1 (en) 2008-03-14 2010-02-25 Angela Brodie Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens;Synthesis In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity
MX2010013224A (es) * 2008-06-03 2010-12-21 Merck Sharp & Dohme Inhibidores de la actividad de la serina/treonina cinasa.
WO2009148916A1 (en) * 2008-06-03 2009-12-10 Merck & Co., Inc. Inhibitors of akt activity
JP2012516900A (ja) 2009-02-05 2012-07-26 トーカイ ファーマシューティカルズ，インク． ステロイド性ｃｙｐ１７阻害剤／抗アンドロゲン剤の新しいプロドラッグ
PE20120534A1 (es) * 2009-02-13 2012-05-10 Bayer Pharma AG PIRIMIDINAS FUSIONADAS COMO INHIBIDORES DE Akt
US8168652B2 (en) 2009-03-12 2012-05-01 Merck Sharp & Dohme Corp. Inhibitors of AKT activity
WO2010114780A1 (en) * 2009-04-01 2010-10-07 Merck Sharp & Dohme Corp. Inhibitors of akt activity
UA109417C2 (uk) 2009-10-14 2015-08-25 Мерк Шарп Енд Доме Корп. ЗАМІЩЕНІ ПІПЕРИДИНИ, ЯКІ ПІДВИЩУЮТЬ АКТИВНІСТЬ p53, І ЇХ ЗАСТОСУВАННЯ
AU2011209649A1 (en) * 2010-01-27 2012-08-09 Vertex Pharmaceuticals Incorporated Pyrazolopyrazine kinase inhibitors
US8999957B2 (en) 2010-06-24 2015-04-07 Merck Sharp & Dohme Corp. Heterocyclic compounds as ERK inhibitors
CN103384670B (zh) * 2010-07-28 2016-05-25 拜耳知识产权有限责任公司 取代的咪唑并[1,2-b]哒嗪
US8518907B2 (en) 2010-08-02 2013-08-27 Merck Sharp & Dohme Corp. RNA interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (CTNNB1) gene expression using short interfering nucleic acid (siNA)
EP4079856A1 (de) 2010-08-17 2022-10-26 Sirna Therapeutics, Inc. Rna-interferenz-vermittelte hemmung der hepatitis b-virus (hbv)-genexpression mittels kurzer interferierender nukleinsäure (sina)
US8946216B2 (en) 2010-09-01 2015-02-03 Merck Sharp & Dohme Corp. Indazole derivatives useful as ERK inhibitors
WO2012058210A1 (en) 2010-10-29 2012-05-03 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA)
WO2012087772A1 (en) 2010-12-21 2012-06-28 Schering Corporation Indazole derivatives useful as erk inhibitors
BR112013025353A8 (pt) 2011-04-01 2018-01-02 Genentech Inc combinação de a) um composto de fórmula ia, composto de fórmula ia ou um sal farmaceuticamente aceitável do mesmo, método para tratamento de um distúrbio hiperproliferativo em um mamífero, uso de um composto de fórmula ia ou um sal farmaceuticamente aceitável do mesmo, kit e produto
JP6147246B2 (ja) 2011-04-01 2017-06-14 ジェネンテック， インコーポレイテッド Ａｋｔ及びｍｅｋ阻害剤化合物の組み合わせ、及び使用方法
US9023865B2 (en) 2011-10-27 2015-05-05 Merck Sharp & Dohme Corp. Compounds that are ERK inhibitors
US9408885B2 (en) 2011-12-01 2016-08-09 Vib Vzw Combinations of therapeutic agents for treating melanoma
WO2013165816A2 (en) 2012-05-02 2013-11-07 Merck Sharp & Dohme Corp. SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS
MX2015004041A (es) 2012-09-28 2015-07-06 Merck Sharp & Dohme Compuestos novedosos que son inhibidores de erk.
CA2892361A1 (en) 2012-11-28 2014-06-05 Merck Sharp & Dohme Corp. Use of a wee1 inhibitor for treating a cancer characterized by low pkmyt1 expression levels
RU2690663C2 (ru) 2012-12-20 2019-06-05 Мерк Шарп И Доум Корп. Замещенные имидазопиридины в качестве ингибиторов hdm2
KR101470115B1 (ko) * 2013-01-09 2014-12-05 동국대학교 산학협력단 2-(페닐에티닐)티에노[3,4-b]피라진 유도체 및 이를 포함하는 암의 예방 또는 치료용 약학적 조성물
WO2014120748A1 (en) 2013-01-30 2014-08-07 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as hdm2 inhibitors
SG11201507093WA (en) 2013-03-14 2015-10-29 Univ Maryland Baltimore Office Of Technology Transfer Androgen receptor down-regulating agents and uses thereof
RU2016104643A (ru) 2013-08-12 2017-09-19 Токай Фармасьютикалз, Инк. Биомаркёры для лечения неопластических заболеваний с применением нацеленных на андроген методов лечения
US20160194368A1 (en) 2013-09-03 2016-07-07 Moderna Therapeutics, Inc. Circular polynucleotides
JOP20190055A1 (ar) 2016-09-26 2019-03-24 Merck Sharp & Dohme أجسام مضادة ضد cd27
SG11201908813QA (en) 2017-04-13 2019-10-30 Aduro Biotech Holdings Europe B V Anti-sirp alpha antibodies
EP3706742B1 (de) 2017-11-08 2023-03-15 Merck Sharp & Dohme LLC Prmt5-inhibitoren
WO2019148412A1 (en) 2018-02-01 2019-08-08 Merck Sharp & Dohme Corp. Anti-pd-1/lag3 bispecific antibodies
EP3833667B1 (de) 2018-08-07 2024-03-13 Merck Sharp & Dohme LLC Prmt5-inhibitoren
WO2020033282A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors
CN115087638B (zh) 2019-12-17 2023-11-24 默沙东公司 Prmt5抑制剂

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3431262A (en) * 1968-03-26 1969-03-04 American Home Prod Pyrazolo quinoxalines
JPS5416497A (en) * 1977-07-08 1979-02-07 Nippon Soda Co Ltd Aminooxopyrrolopyrazine compounds and their preparation
TW251284B (de) 1992-11-02 1995-07-11 Pfizer
US5474995A (en) * 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
EP0807104A2 (de) 1995-02-02 1997-11-19 Smithkline Beecham Plc Heterozyklische verbindungen mit 5ht2c rezeptor antagonismus
CA2212061A1 (en) 1995-02-02 1996-08-08 Laramie Mary Gaster Indole derivatives as 5-ht receptor antagonist
GB9525702D0 (en) 1995-12-15 1996-02-14 Ciba Geigy Ag Process for activating a kinase
US20020127214A1 (en) * 1995-11-16 2002-09-12 Hemmings Brian Arthur RAC-protein kinase as therapeutic agent or in diagnostics
US20020132326A1 (en) * 1995-12-15 2002-09-19 Hemmings Brian A. Process for activating a kinase
ATE274053T1 (de) 1995-11-16 2004-09-15 Novartis Pharma Gmbh Methode zur identifizierung von verbindungen die mit rac proteine kinase interagieren
JP2000502097A (ja) 1995-12-20 2000-02-22 メディカル、リサーチ、カウンシル タンパク質合成の制御、および作用薬のスクリーニング法
WO1997049704A1 (en) 1996-06-27 1997-12-31 Janssen Pharmaceutica N.V. N-[4-(heteroarylmethyl)phenyl]-heteroarylamines
US6060491A (en) * 1997-06-19 2000-05-09 Dupont Pharmaceuticals 6-membered aromatics as factor Xa inhibitors
WO1999007701A1 (en) * 1997-08-05 1999-02-18 Sugen, Inc. Tricyclic quinoxaline derivatives as protein tyrosine kinase inhibitors
WO1999042461A1 (en) 1998-02-23 1999-08-26 Warner-Lambert Company Substituted quinoxaline derivatives as interleukin-8 receptor antagonists
GB0005642D0 (en) 2000-03-10 2000-05-03 Astrazeneca Uk Ltd Chemical compounds
IL152807A0 (en) 2000-05-30 2003-06-24 Peptor Ltd Protein kinase inhibitors
DE10058663A1 (de) * 2000-11-25 2002-05-29 Merck Patent Gmbh Verwendung von Thienopyrimidinen
JP2002284684A (ja) * 2001-01-16 2002-10-03 Japan Science & Technology Corp チエノイソキノロン含有抗菌抗ウィルス剤および抗腫瘍剤
JP2002220338A (ja) * 2001-01-26 2002-08-09 Banyu Pharmaceut Co Ltd ビアリールウレア化合物又はその塩を有効成分として含有するＣｄｋ４及び／又はＣｄｋ６阻害剤
US6958334B2 (en) * 2001-04-10 2005-10-25 Merck & Co., Inc. Inhibitors of Akt activity
US6960584B2 (en) * 2001-04-10 2005-11-01 Merck & Co., Inc. Inhibitors of Akt activity
US20040116433A1 (en) * 2002-04-08 2004-06-17 Owens Andrew Pate Inhibitors of akt activity
JP2004527531A (ja) * 2001-04-10 2004-09-09 メルク　エンド　カムパニー　インコーポレーテッド 癌を治療する方法
CA2442270C (en) * 2001-04-10 2009-09-08 Merck & Co., Inc. Inhibitors of akt activity
WO2003084473A2 (en) 2002-04-08 2003-10-16 Merck & Co., Inc. Method of treating cancer
US7273869B2 (en) 2002-04-08 2007-09-25 Merck & Co., Inc. Inhibitors of Akt activity
CA2480880C (en) * 2002-04-08 2011-03-22 Merck & Co., Inc. Inhibitors of akt activity
AU2003226250B2 (en) 2002-04-08 2007-08-16 Merck Sharp & Dohme Corp. Inhibitors of Akt activity
WO2003086394A1 (en) 2002-04-08 2003-10-23 Merck & Co., Inc. Inhibitors of akt activity
US20040102360A1 (en) * 2002-10-30 2004-05-27 Barnett Stanley F. Combination therapy

Also Published As

Publication number Publication date
EP1558586A4 (de) 2007-06-27
CA2501365A1 (en) 2004-05-21
EP1558586B1 (de) 2011-03-30
ATE503483T1 (de) 2011-04-15
WO2004041162A3 (en) 2004-07-29
JP2006507299A (ja) 2006-03-02
CA2501365C (en) 2011-05-31
US20050288294A1 (en) 2005-12-29
WO2004041162A2 (en) 2004-05-21
US7399764B2 (en) 2008-07-15
AU2003284981A1 (en) 2004-06-07
EP1558586A2 (de) 2005-08-03
AU2003284981B2 (en) 2009-05-28

Similar Documents

Publication Publication Date Title
DE60336576D1 (de) Hemmer der akt aktivität
DE602004026047D1 (de) Hemmer der akt aktivität
DE602004023838D1 (de) Hemmer der akt aktivität
WO2004096130A3 (en) Inhibitors of akt activity
ATE512957T1 (de) Hemmer der akt aktivität
DE602005026509D1 (de) Hemmer der akt aktivität
ATE400274T1 (de) Hemmstoffe der akt aktivität
RU2394826C2 (ru) Дизамещенные пиразолобензодиазепины, используемые в качестве ингибиторов cdk2 и ангиогенеза, а также для лечения злокачественных новообразований молочной железы, толстого кишечника, легкого и предстательной железы
WO2003086279A3 (en) Inhibitors of akt activity
WO2006036395A3 (en) Inhibitors of akt activity
CA2480800A1 (en) Inhibitors of akt activity
MXPA05013349A (es) Derivados de 2-amino-pirimidina como inhibidores de quinasa raf.
WO2003024967A3 (en) Indolizines as kinase protein inhibitors
TW200611907A (en) Fused heterocyclic compound
DK1678166T3 (da) Proteinkinaseinhibitorer
NZ533310A (en) Benzimidazoles useful as protein kinase inhibitors
TW200519096A (en) Quinazoline analogs as receptor tyrosine kinase inhibitors
EA201000101A1 (ru) Производные пиримидина 934
MX2007003104A (es) Nuevos derivados de ftalazinona, como inhibidores de cinasa aurora-a.
ATE403653T1 (de) Pyridin-substituierte furanderivate als raf- kinase inhibitoren
EA200400475A1 (ru) Замещенные производные бензимидазола и их применение для лечения злокачественной опухоли
MX2023004802A (es) Compuestos espiro heterocíclicos y métodos de uso.
ATE507218T1 (de) Benzodiazepin-derivate als rock-kinasen hemmer
MXPA05009151A (es) Inhibidores de cinasa heterociclica.
BR0311960A (pt) Derivado de 1-[ (indol-3-il) carbonil] piperazina, uso do mesmo e composição farmacêutica

Legal Events

Date Code Title Description
R081 Change of applicant/patentee

Ref document number: 1558586

Country of ref document: EP

Owner name: SCHERING CORPORATION, US

Free format text: FORMER OWNER: MERCK SHARP & DOHME CORP., RAHWAY, US

Effective date: 20121213

R082 Change of representative

Ref document number: 1558586

Country of ref document: EP

Representative=s name: ABITZ & PARTNER, DE

Effective date: 20121213